Emergent BioSolutions Completes Sale of Baltimore-Bayview Facility to Syngene International

, MT Newswires -  5:16 PM ET 3/19/2025 mergers-and-acquisitions

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

05:16 PM EDT, 03/19/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) completed the sale of its Baltimore-Bayview drug substance manufacturing facility in Maryland to India's Syngene International for $36.5 million.

The sale covers the facility's assets and equipment, Emergent said Wednesday in a statement.

Emergent retains the option to access manufacturing services and capacity at the site to support future growth and pandemic response efforts in partnership with Syngene.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.